Close Menu

NEW YORK ─ Saladax Biomedical said on Wednesday that it has received de novo clearance from the US Food and Drug Administration for a rapid blood test that measures clozapine levels in psychiatric patients. The MyCare Psychiatry Clozapine Assay provides results in 10 minutes and gives clinicians access to quantitative blood levels of the psychotherapeutic drug, the firm said.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.